Fig. 4

CAPE promoted long-term engraftment of HSPCs in the BM. a Percentages of CD45.1⁺ cells in PB every 4 weeks after secondary transplantation until the 16th week. BM MNCs (5 × 10⁵) were harvested from the primary recipient mice 20 h after BMT and the various treatments and were then mixed with 5 × 10⁵ competitor CD45.2⁺ BM MNCs and co-transplanted into irradiated CD45.2 mice (secondary recipients). Sixteen mice per group.b–f Donor CD45.1⁺ blood lineage cell percentages in the secondary recipient PB detected in the 16th week after secondary transplantation. n = 8 in blue, n = 9 in red. g, h Representative dot plots and percentage of BM Lin^–Sca-1⁺c-kit⁺CD45.1⁺ cells from secondary recipients (n = 16). BM cells were harvested from the secondary recipient mice at the 16th week after competitive BMT. Blue indicates vehicle group, red indicates CAPE group. *P < 0.05, **P < 0.01, ***P < 0.001, CAPE vs vehicle. BM bone marrow, CAPE caffeic acid phenethyl ester, SSC side scatter, NS not significant, PB peripheral blood